Abstract
A modified version of the CORAL software (http://www.insilico.eu/coral) allows building up the classification model for the case of the Yes/No data on the anti-sarcoma activity of organic compounds. Three random splits into the sub-training, calibration, and test sets of the data for 3017 compounds were examined. The performance of the proposed approach is satisfactory. The average values of the statistical characteristics for external test set on three random splits are as follows: n=1173-1234, sensitivity = 0.8903±0.0390, specificity = 0.9869±0.0013, and accuracy = 0.9759±0.0043. Mechanistic interpretation of the suggested model is discussed.
Keywords: QSAR, Monte Carlo method, CORAL software, classification model, anti-sarcoma activity
Current Topics in Medicinal Chemistry
Title:CORAL: Classification Model for Predictions of Anti-Sarcoma Activity
Volume: 12 Issue: 24
Author(s): A.A. Toropov, A.P. Toropova, E. Benfenati, G. Gini, D. Leszczynska and J. Leszczynski
Affiliation:
Keywords: QSAR, Monte Carlo method, CORAL software, classification model, anti-sarcoma activity
Abstract: A modified version of the CORAL software (http://www.insilico.eu/coral) allows building up the classification model for the case of the Yes/No data on the anti-sarcoma activity of organic compounds. Three random splits into the sub-training, calibration, and test sets of the data for 3017 compounds were examined. The performance of the proposed approach is satisfactory. The average values of the statistical characteristics for external test set on three random splits are as follows: n=1173-1234, sensitivity = 0.8903±0.0390, specificity = 0.9869±0.0013, and accuracy = 0.9759±0.0043. Mechanistic interpretation of the suggested model is discussed.
Export Options
About this article
Cite this article as:
Toropov A.A., Toropova A.P., Benfenati E., Gini G., Leszczynska D. and Leszczynski J., CORAL: Classification Model for Predictions of Anti-Sarcoma Activity, Current Topics in Medicinal Chemistry 2012; 12 (24) . https://dx.doi.org/10.2174/1568026611212240004
DOI https://dx.doi.org/10.2174/1568026611212240004 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thyroid Hormone Modulation of Immunity: Its Participation in Chronic Stress-Induced Immune Alterations
Current Immunology Reviews (Discontinued) Phytoecdysteroids - From Isolation to Their Effects on Humans
Current Medicinal Chemistry Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Structural and Functional Characterization of the Proteins Responsible for N<sup>6</sup>-Methyladenosine Modification and Recognition
Current Protein & Peptide Science Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity
Medicinal Chemistry Reviews - Online (Discontinued) NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets Src Inhibitors and Angiogenesis
Current Pharmaceutical Design Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design Can PPARγ Ligands Be Used in Cancer Therapy?
Current Medicinal Chemistry - Anti-Cancer Agents Polynucleotide Kinase as a Potential Target for Enhancing Cytotoxicity by Ionizing Radiation and Topoisomerase I Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Recent Development in Nano-Sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs
Recent Patents on Anti-Cancer Drug Discovery Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Antiviral Properties of Quinolone-based Drugs
Current Drug Targets - Infectious Disorders Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry